Tacrolimus (Prograf) for Ulcerative Colitis
|1,590 Patients Studied||105 Studies (View)|
Definition: Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug that is mainly used after allogeneic organ transplant to reduce the activity of the patient's immune system and so lower the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, exacerbations of minimal change disease, and the skin condition vitiligo. Ulcerative colitis (Colitis ulcerosa, UC) is a form of inflammatory bowel disease (IBD). Ulcerative colitis is a form of colitis, a disease of the intestine, specifically the large intestine or colon, that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually constant diarrhea mixed with blood, of gradual onset. IBD is often confused with irritable bowel syndrome (IBS), a troublesome, but much less serious, condition. (SOURCE: Wikipedia)
Where does Tacrolimus (Prograf) rank compared to other Ulcerative Colitis treatments?
#20Health experts published 14 studies on Moxibustion and Ulcerative Colitis making Moxibustion the #20 most researched treatment. In research involving Ulcerative Colitis, experts have concluded that Moxibustion is effective in 4 studies and safe in 3 studies.
Health experts published 164 studies on Methotrexate and Ulcerative Colitis making Methotrexate the #21 most researched treatment. In research involving Ulcerative Colitis, experts have concluded that Methotrexate is effective in 21 studies and safe in 6 studies.
What peer treatments do patients prefer?
What does the FDA say about side effects?
Most Researched Conditions
What other conditions have been studied?
What treatments have patients discontinued using?
What treatments are patients switching to?